- Home
- PVLA
as 06-20-2025 3:40pm EST
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 253.2M | IPO Year: | N/A |
| Target Price: | $46.29 | AVG Volume (30 days): | 81.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.17 - $29.27 | Next Earning Date: | 08-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palvella Therapeutics Inc. Common Stock News
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
GlobeNewswire
12 days ago
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
GlobeNewswire
25 days ago
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
GuruFocus.com
a month ago
Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...
GlobeNewswire
a month ago
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire
2 months ago
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
Insider Monkey
2 months ago
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025
Compare PVLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.